Compare Neurocrine Biosciences Inc (NBIX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Schwab US Large Cap Growth ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Schwab US Large Cap Growth ETF trades at $35.04. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SCHG | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $35.94 |
52-Week Low | $123.10 | $28.10 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SCHG trades at $35.25, down 0.79% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional interest and offers exposure to large-cap growth stocks at a competitive expense ratio. Recent news highlights SCHG's historical outperformance versus the S&P 500 and ongoing comparisons with peers like QQQM and VUG.
Long-term growth potential remains supported by SCHG's track record, though concentration risk in top holdings and market volatility pose challenges. The ETF's low-cost structure and growth focus present opportunities for investors seeking diversified large-cap exposure, but requires monitoring of valuation levels and sector rotations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
